Redefining Every Stage of Investment (RESI) Seed to Exit Conference Redefining Every Stage of Investment (RESI) Seed to Exit CertaraSeptember 5, 2025
The Pharmacometrics Africa Conference 2025 (PMXAC-2025) Conference The Pharmacometrics Africa Conference 2025 (PMXAC-2025) CertaraSeptember 4, 2025
Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies Live Events Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies CertaraSeptember 4, 2025
The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape Webinar The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape CertaraSeptember 3, 2025
Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH) Webinar Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH) Danielle PillsburyAugust 29, 2025
Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value Webinar Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value CertaraAugust 21, 2025
ToxStudio®: In silico tools to accelerate toxicology assessments Webinar ToxStudio®: In silico tools to accelerate toxicology assessments CertaraAugust 19, 2025
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma Publication Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…CertaraAugust 13, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial Publication Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…CertaraAugust 13, 2025